Emergence of dual resistance to zidovudine and lamivudine in HIV-1- infected patients treated with zidovudine plus lamivudine as initial therapy

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 23, Issue 1, 2000, Pages 26-34

  Kuritzkes, Daniel R ^a,e   Shugarts, David ^a   Bakhtiari, Minoo ^a   Poticha, David ^a   Johnson, Judy ^b   Rubin, Marc ^b   Gingeras, Thomas R ^c   Kennedy, Mitchell ^c   Eron, Joseph J ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Thermo Fisher Scientific   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Dual resistance; Lamivudine; Zidovudine

Indexed keywords

LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

AMINO ACID SEQUENCE; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; FOLLOW UP; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MUTATION RATE; PHENOTYPE; PRIORITY JOURNAL; REVERTANT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034048599     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200001010-00004     Document Type: Article

References (29)

1. Gao Q, Gu Z, Hiscott J, Dionne G, Wainberg MA. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993;37:130-3.
2. Boucher CAB, Cammack N, Schipper P, et al. High-level resistance to (-)enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993;37:2231-4.
3. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993;90:5653-6.
4. Schinazi RF, Lloyd RM, Nguyen MH, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875-81.
5. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-9.
6. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, ZDV, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
7. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996;276:118-25.
8. Phillips AN, Eron J, Bartlett J, et al. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. AIDS 1997;11:169-70.
9. CAESAR Coordinating Committee. Randomized trial of addition of lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349:1413-21.
10. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 1998;280: 35-41.
11. Tashima K, Staszewski S, Stryker R, et al. A phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 48 weeks (study DMP 266-006) [abstract LB16]. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, U.S.A., 1999.
12. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269:696-9.
13. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologie response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996;10:975-81.
14. Kemp S, Shi C, Bloor S, Harrigan PR, Mellors J, Larder B. A novel polymorphism at codon 333 of HIV-1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J Virol 1998;72:5093-98.
15. Nijhuis M, Schuurman R, deJong D, et al. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis 1997;176:398-405.
16. Gass RJA, Shugarts D, Young R, Allen M, Rosandich M, Kuritzkes DR. Emergence of dual resistance to zidovudine (ZDV) and lamivudine (3TC) in clinical HIV-1 isolates from patients receiving ZDV/3TC combination therapy. Antiviral Ther 1998;3:97-102.
17. Jackson BJ, Coombs RW, Sannerud K, Rhame FS, Balfour HH. Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J Clin Microbiol 1988;26:1416-8.
18. Japour AJ, Mayers DL, Johnson VA, et al. A standardized peripheral blood mononuclear cell culture assay for the determination of drug susceptibilities of clinical human immunodeficiency virus-1 (HIV-1) isolates. Antimicrob Agents Chemother 1993;37:1095-1101.
19. Kozal M, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996;2:753-9.
20. Myers G, Korber B, Hahn B, et al. Human retroviruses and AIDS 1995. Los Alamos, NM: Theoretical Biology and Biophysics, 1995.
21. Bloor S, Hertogs K, De Vroey V, Miller V, Sturmer M, Larder B. Lamivudine-resistant HIV-1 clinical isolates lacking the Met184Val mutation have novel polymorphisms in RT [abstract 25]. Antiviral Ther 1999;4(Suppl 1):19.
22. Harrigan PR, Kinghorn I, Bloor S, et al. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 1996; 70:5930-4.
23. Miller V, Phillips AN, Rottman C, et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 1998;177:1521-32.
24. Rusconi S, DePasquale MP, Milazzo L, et al. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1 infected patients in an ongoing open-label trial. Antiviral Therapy 1997;2:39-46.
25. Kemp SD, Bloor S. Two distinct mutational pathways in HIV-1 RT confer zidovudine/lamivudine dual resistance [abstract 1]. Antiviral Ther 1997;2(Suppl 5):21-2.
26. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-8.
27. Larder BA. 3′-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992;36:2664-9.
28. Wakefield JK, Jablonski SA, Morrow CD. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome. J Virol 1992;66:6806-12.
29. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.